AUROPHARMA:NSE:NSE-Aurobindo Pharma Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1160.5

Change

0.00 (0.00)%

Market Cap

USD 674.02B

Volume

0.69M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
AUROPHARMA:NSE
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-280.15 (-4.86%)

USD 1,533.20B
CIPLA:NSE Cipla Limited

-80.45 (-5.38%)

USD 1,164.75B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+38.80 (+1.19%)

USD 1,092.48B
MANKIND:NSE Mankind Pharma Ltd

+23.50 (+0.97%)

USD 1,000.40B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-41.50 (-3.60%)

USD 953.29B
LUPIN:NSE Lupin Limited

-124.65 (-5.95%)

USD 925.89B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-35.00 (-3.88%)

USD 891.92B
ABBOTINDIA:NSE Abbott India Limited

-831.90 (-2.78%)

USD 653.01B
ALKEM:NSE Alkem Laboratories Limited

-142.85 (-2.87%)

USD 583.68B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-45.40 (-2.94%)

USD 434.87B

ETFs Containing AUROPHARMA:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -14.24% 58% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -14.24% 58% F 65% D
Trailing 12 Months  
Capital Gain 6.59% 49% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.59% 49% F 61% D-
Trailing 5 Years  
Capital Gain 180.89% 43% F 35% F
Dividend Return 4.96% 38% F 23% F
Total Return 185.85% 43% F 35% F
Average Annual (5 Year Horizon)  
Capital Gain 18.85% 40% F 32% F
Dividend Return 19.52% 40% F 33% F
Total Return 0.67% 66% D+ 51% F
Risk Return Profile  
Volatility (Standard Deviation) 57.67% 35% F 40% F
Risk Adjusted Return 33.85% 26% F 22% F
Market Capitalization 674.02B 91% A- 94% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector